Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2016

Open Access 01-12-2016 | Research article

Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study

Authors: Gebrehiwot Teklay, Tsigemariam Teklu, Befikadu Legesse, Kiros Tedla, Eveline Klinkenberg

Published in: BMC Public Health | Issue 1/2016

Login to get access

Abstract

Background

Isoniazid preventive therapy is a key public health intervention for the prevention of tuberculosis disease among people living with HIV. Despite the confirmed efficacy of isoniazid preventive therapy and global recommendations existing for decades, its implementation remains limited. In resource constrained settings, few have investigated why isoniazid preventive therapy is not implemented on full scale. This study was designed to investigate the level of isoniazid preventive therapy implementation and reasons for suboptimal implementation in Tigray region of Ethiopia.

Methods

A review of patient records combined with a qualitative study using in-depth interviews and focus group discussions was conducted in 11 hospitals providing isoniazid preventive therapy in the Tigray Region. The study participants were health providers working in the HIV clinics of the 11 hospitals in the province. Health providers were interviewed about their experience of providing isoniazid preventive therapy and challenges faced during its implementation. All conversations were audio-recorded. Record review of 16,443 HIV patients registered for care in these hospitals between September 2011 and April 2014 was done to determine isoniazid preventive therapy utilization. Data were collected from April to August 2014.

Results

Fifty health providers participated in the study. Overall isoniazid preventive therapy coverage of the region was estimated to be 20 %. Isoniazid stock out, fear of creating isoniazid resistance, problems in patient acceptance, and lack of commitment of health managers to scale up the program were indicated by health providers as the main barriers hindering implementation of isoniazid preventive therapy.

Conclusion

Implementation of isoniazid preventive therapy in Tigray region of Ethiopia had low coverage. Frequent interruption of isoniazid supplies raises the concern of interrupted therapy resulting in creation of isoniazid resistance. Health managers, drug suppliers and partners working in HIV and tuberculosis programs should be committed to ensure an uninterrupted supply of isoniazid and full scale implementation of isoniazid preventive therapy to eligible people living with HIV.
Appendix
Available only for authorised users
Literature
1.
World Health Organization. Guidelines for intensified tuberculosis case-finding and isoniazid preventive therapy for people living with HIV in resource-constrained settings. Geneva: WHO; 2011.
2.
3.
Federal Ministry of Health of Ethiopia. Implementation guideline for TB/HIV collaborative activities in Ethiopia. Addis Ababa: FMoH; 2007.
4.
Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2004;1:CD000171.PubMed
5.
Yirdaw KD, Jerene D, Gashu Z, Edginton ME, Kumar AMV, Letamo Y, Feleke B, Teklu AM, Zewdu S, Weiss B, Ruff A. Beneficial effect of isoniazid preventive therapy and antiretroviral therapy on the incidence of tuberculosis in people living with HIV in Ethiopia. PLoS One. 2014;9(8):e104557. doi:10.​1371/​journal.​pone.​0104557.CrossRefPubMedPubMedCentral
6.
Assebe LF, Reda HL, Wubeneh AD, Lerebo WT, Lambert SM. The effect of isoniazid preventive therapy on incidence of tuberculosis among HIV-infected clients under pre-ART care, Jimma, Ethiopia: a retrospective cohort study. BMC Public Health. 2015;15:346.CrossRefPubMedPubMedCentral
7.
Grant AD, Charalambous S, Fielding KL, Jay KH, Corbett EL, Chaisson RE, De Cock KM, Hayes RJ, Churchyard GJ. Effect of routine isoniazid preventive therapy on tuberculosis incidence among HIV-infected men in South Africa: a novel randomized incremental recruitment study. JAMA. 2005;293:2719–25.CrossRefPubMed
8.
Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, Gray GE, McIntyre JA, Chaisson RE, Martinson NA. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS. 2009;23(5):631–6.CrossRefPubMedPubMedCentral
9.
Zar HJ, Cotton MF, Strauss S, Karpakis J, Hussey G, Schaaf HS, Rabie H, Lombard CJ. Effect of isoniazid prophylaxis on mortality and incidence of tuberculosis in children with HIV: randomised controlled trial. BMJ. 2006;334(7585):136.CrossRefPubMedPubMedCentral
10.
Bucher HC, Griffith LE, Guyatt GH, Sudre P, Naef M, Sendi P, Battegay M. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS. 1999;13(4):501–7.CrossRefPubMed
11.
Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev. 2010;1:CD000171. Epub 2010 Jan 20.PubMed
12.
World Health Organization. Global tuberculosis report 2013. Geneva: WHO; 2013.
13.
14.
Getahun H, Granich R, Sculier D, Gunneberg C, Blanc L, Nunn P, Raviglione M. Implementation of isoniazid preventive therapy for people living with HIV worldwide: barriers and solutions. AIDS. 2010;24 Suppl 5:S57–65.CrossRefPubMed
15.
Date AA, Vitoria M, Granich R, Banda M, Fox YM, Gilks C. Implementation of co-trimoxazole prophylaxis and isoniazid preventive therapy for people living with HIV. Bull World Health Organ. 2010;88:253–9.CrossRefPubMed
16.
Mindachew M, Deribew A, Memiah P, Biadgilign S. Perceived barriers to the implementation of Isoniazid preventive therapy for people living with HIV in resource constrained settings: a qualitative study. Pan Afr Med J. 2014;17:26.CrossRefPubMedPubMedCentral
17.
Lester R, Hamilton R, Charalambous S, Dwadwa T, Chandler C, Churchyard GJ, Grant AD. Barriers to implementation of isoniazid preventive therapy in HIV clinics: a qualitative study. AIDS. 2010;24 Suppl 5:S45–8.CrossRefPubMed
18.
19.
Wesen A, Mitike G. Provision and awareness for isoniazid preventive therapy among PLHIV in Addis Ababa, Ethiopia. BMC Int Health Hum Rights. 2012;12(1):2.CrossRefPubMedPubMedCentral
20.
Denegetu AW, Dolamo BL. Tuberculosis case finding and isoniazid preventive therapy among people living with HIV at public health facilities of Addis Ababa, Ethiopia: a cross-sectional facility based study. BMC Public Health. 2014;14:52.CrossRefPubMedPubMedCentral
21.
22.
Berhanemeskel E, Gedif T. Assessment of supply chain management of HIV/AIDS related commodities in selected public hospitals and health centers in Addis Ababa, Ethiopia. Addis Ababa University electronic Thesis and dissertation June 2014. Available at: http://​etd.​aau.​edu.​et/​handle/​123456789/​6099 (Accessed 8 Dec 2015).
23.
Daniel G, Tegegnework H, Demissie T, Reithinger R. Pilot assessment of supply chains for pharmaceuticals and medical commodities for malaria, tuberculosis and HIV infection in Ethiopia. Trans R Soc Trop Med Hyg. 2012;106(1):60–2.CrossRefPubMed
24.
25.
Zaeh S, Kempker R, Stenehjem E, Blumberg HM, Temesgen O, Ofotokun I, Tenna A. Improving tuberculosis screening and isoniazid preventive therapy in an HIV clinic in Addis Ababa, Ethiopia. Int J Tuberc Lung Dis. 2013;17(11):1396–401.CrossRefPubMedPubMedCentral
26.
Moolphate S, Lawpoolsri S, Pungrassami P, Sanguanwongse N, Yamada N, Kaewkungwal J. Barriers to and motivations for the implementation of a treatment programme for latent tuberculosis infectionusing isoniazid for people living with HIV, in upper northern Thailand. Glob J Health Sci. 2013;5(4):60–70. doi:10.​5539/​gjhs.​v5n4p60.
27.
Durovni B, Cavalcante SC, Saraceni V, Vellozo V, Israel G, King BS, Cohn S, Efron A, Pacheco AG, Moulton LH, Chaisson RE, Golub JE. The implementation of isoniazid preventive therapy in HIV clinics: the experience from the TB/HIV in Rio (THRio) Study. AIDS. 2010;24 Suppl 5:S49–56.CrossRefPubMedPubMedCentral
28.
Balcells ME, Thomas SL, Godfrey-Faussett P, Grant AD. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006;12(5):744–51.CrossRefPubMedPubMedCentral
29.
30.
Van Halsema CL, Fielding KL, Chihota VN, Russell EC, Lewis JJC, Churchyard GJ, Grant AD. Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting. AIDS. 2010;24(7):1051–5.CrossRefPubMed
31.
MRA van Cleeff, LE Kivihya-Ndugga, H Meme, JA Odhiambo and PR Klatser. The role and performance of chest X-ray for the diagnosis of tuberculosis: A cost-effectiveness analysis in Nairobi, Kenya. BMC Infect Dis. 2005; 5:111.
32.
Aït-Khaled N, Alarcon E, Bissell K, Boillot F, Caminero JA, Chiang CY, Clevenbergh P, Dlodlo R, Enarson DA, Enarson P, Ferroussier O, Fujiwara PI, Harries AD, Heldal E, Hinderaker SG, Kim SJ, Lienhardt C, Rieder HL, Rusen ID, Trébucq A, Van Deun A, Wilson N. Isoniazid preventive therapy for people living with HIV: public health challenges and implementation issues. Int J Tuberc Lung Dis. 2009;13(8):927–35.PubMed
33.
Rutherford ME, Hill PC, Triasih R, Sinfield R, van Creve R, Graham SM. Preventive therapy in children exposed to Mycobacterium tuberculosis: problems and solutions. Trop Med Int Health. 2012;17(10):1264–73.CrossRefPubMed
34.
Antonucci G, Girardi E, Raviglione M, Vanacore P, Angarano G, Chirianni A, Pagano G. Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study. Eur Respir J. 2001;18:369–75.CrossRefPubMed
35.
Nolan HM, Goldberg SV, Buskin SE. Hepatotoxicity associated with isoniazid preventive therapy a 7-year survey from a public health tuberculosis clinic. JAMA. 1999;281(11):1014–8.CrossRefPubMed
Metadata
Title
Barriers in the implementation of isoniazid preventive therapy for people living with HIV in Northern Ethiopia: a mixed quantitative and qualitative study
Authors
Gebrehiwot Teklay
Tsigemariam Teklu
Befikadu Legesse
Kiros Tedla
Eveline Klinkenberg
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2016
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-016-3525-8

Other articles of this Issue 1/2016

BMC Public Health 1/2016 Go to the issue

Study protocol

A restaurant-based intervention to promote sales of healthy children’s menu items: the Kids’ Choice Restaurant Program cluster randomized trial

Research article

Spatial analysis of gender variation in the prevalence of hypertension among the middle-aged and elderly population in Zhejiang Province, China

Research article

Estimating the severity distribution of disease in South Korea using EQ-5D-3L: a cross-sectional study

Research article

Does mode of follow-up influence contraceptive use after medical abortion in a low-resource setting? Secondary outcome analysis of a non-inferiority randomized controlled trial

Research article

Sociocultural determinants of anticipated oral cholera vaccine acceptance in three African settings: a meta-analytic approach

Research article

Differences in perceived fairness and health outcomes in two injury compensation systems: a comparative study